CureVac stock enters a new chapter after BioNTech takeover

Published on 09/25/2026 at 10:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CureVac stock is tied to BioNTech's USD 1.25 billion takeover reported on September 25, 2026. Up to 820 jobs are linked to the site review.

CVAC, NL0015436031, Illustration mit AI erstellt.

CureVac stock (ISIN NL0015436031) enters a new chapter after BioNTech's USD 1.25 billion all-stock acquisition, reported by the Financial Times on September 25, 2026. The transaction shifts the investment case from an independent biotechnology company toward assets controlled by BioNTech.

USD 1.25 billion transaction reshapes CureVac

The Financial Times said BioNTech and CureVac joined forces through an all-stock deal valued at USD 1.25 billion. The transaction took about 12 months to close, making the corporate change a measured process rather than a single-session market event.

The commercial consequence is material because CureVac's operating footprint is now being assessed inside BioNTech's broader manufacturing strategy. CureVac develops messenger RNA medicines and vaccines, while the acquirer is concentrating its pipeline and production network on mRNA applications.

Up to 820 jobs tied to site decisions

According to BioNTech in its August 27, 2026 update, potential divestment options for CureVac sites were being explored through the end of September. A report by SWR stated that up to 820 CureVac jobs were threatened, mainly at the Tuebingen site.

That figure gives investors a concrete measure of the restructuring risk. The outcome for the sites can influence how much of CureVac's research, manufacturing capacity and workforce remains within the combined group.

CureVac stock stays below yearly high

CureVac stock was quoted at USD 4.66 on Nasdaq on January 6, 2026. That level was 18.5 percent below the 52-week high of USD 5.72 and above the 52-week low of USD 2.48, showing a wide trading corridor for the listed security.

The cited market profile put CureVac's market capitalization at USD 1.05 billion and trailing twelve-month revenue at USD 70.74 million. The comparison between market value and revenue underlines why the BioNTech transaction and the future use of CureVac's assets matter more than a standalone sales trend.